Trading at an extremely cheap valuation despite strong growth and new GLP-1 partnerships.

The restoration of mail-order access for Mifepristone supports the growth of telehealth platforms specializing in reproductive health.

Host took a position based on personal product usage and following moves by respected community analysts.

Host exited position warning of a potential cool-down after a successful trade leg.

Highlighted as a retail 'hallucination yield' play driven by AI suggestions.

Viewed as a less attractive alternative to LFMD which owns its own supply chain.

Positive price action described as a 'sick candle' indicating strong upward momentum.

Highly bullish following a partnership with Eli Lilly; market reaction is considered muted relative to the deal's scale.

Described as having 'lost its juice' after a pump-and-dump reaction to a partnership announcement.

Contrarian long view at the $19 price level.